ArticleFrontiers in neurology2025
The association between blood urea nitrogen to albumin ratio and cognitive function in Parkinson's disease patients.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment is a significant complication in Parkinson's disease (PD), impacting quality of life and increasing caregiver burden. This study investigates the association between the blood urea nitrogen to albumin ratio (BAR) and cognitive impairment in PD patients, aiming to identify BAR as a potential biomarker for early detection and monitoring of cognitive decline. Methods: Data from 1,312 PD patients were extracted from the PPMI database. The cognitive assessment tool was the Montreal Cognitive Assessment (MoCA) score and other cognitive metrics. The association between BAR and cognitive impairment was assessed using multivariate linear regression models to evaluate the continuous relationship, and logistic regression models to examine the binary outcomes. Furthermore, subgroup and sensitivity analyses were carried out to ensure the reliability of the results. Results: Higher BAR levels were significantly associated with lower MoCA scores in PD patients, independent of other confounding variables ( Conclusion: This study underscores the potential utility of BAR as a biomarker for cognitive impairment in PD. Future prospective cohort studies are warranted to validate these findings and explore the potential of BAR in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.